ASP recommendation accepted | ID physician recommendation accepted | p-value | |
---|---|---|---|
(n= 100) | (n= 43) | ||
Median age, years (interquartile range) | 64 (53ā72) | 58 (50 ā 72) | 0.393 |
Intensive care unit admission within 30 days prior to review (%) | 23 (23.0) | 10 (23.3) | 0.973 |
Median Charlson Comorbidity Index (interquartile range) | 5 (3 ā 8) | 5 (2 ā 8) | 0.255 |
Clinical discipline (%) | 0.754 | ||
ā¢ Hematology-oncology | 36 (36.0) | 12 (27.9) | |
ā¢ Surgery | 29 (29.0) | 12 (27.9) | |
ā¢ Orthopedics | 24 (24.0) | 13 (30.2) | |
ā¢ Medicine | 10 (10.0) | 6 (14.0) | |
ā¢ Others | 1 (1.0) | 0 (0) | |
Type of infection (%): | 0.247 | ||
ā¢ Intra-abdominal infection | 23 (23.0) | 9 (20.9) | |
ā¢ Bloodstream | 12 (12.0) | 6 (14.0) | |
ā¢ Bone and joint infection | 14 (14.0) | 12 (27.9) | |
ā¢ Skin and soft tissue infection | 15 (15.0) | 6 (14.0) | |
ā¢ Respiratory tract infection | 6 (6.0) | 2 (4.7) | |
ā¢ Urinary tract infection | 10 (10.0) | 6 (14.0) | |
ā¢ Othersa | 20 (20.0) | 2 (4.7) | |
Type of ASP recommendations:b | 0.172 | ||
ā¢ Discontinue antibiotics | 26 | 5 | |
ā¢ De-escalate antibiotics | 30 | 16 | |
ā¢ Escalate antibiotics | 8 | 5 | |
ā¢ Intravenous to oral antibiotic switch | 6 | 2 | |
ā¢ Dose optimization | 16 | 5 | |
ā¢ Duration of antibiotics | 0 | 2 | |
ā¢ Discontinue duplicate antibiotic coverage | 9 | 7 | |
ā¢ Other recommendationsc | 10 | 3 | |
Outcomes (%): | |||
ā¢ 30-day mortality | 7 (7.0) | 3 (7.0) | 1.000 |
ā¢ 30-day re-admissiond | 21 (22.6) | 6 (15.0) | 0.358 |
ā¢ Clinical deterioration | 8 (8.0)e | 12 (27.9)f | 0.003 |
āā Persistent fever | 2 (25.0) | 4 (33.3) | |
āā No microbiological clearance | 2 (25.0) | 3 (25.0) | |
āā Lack of physiological improvement | 6 (75.0) | 10 (83.3) |